NCT00116454View on ClinicalTrials.gov

Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis

PHASE3CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Carcinoma, HepatocellularHepatitis, Viral, Human
Interventions
DRUG

131 I-lipiodol

intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment

Trial Locations (1)

75012

Service d'Hépatologie Hôpital Saint Antoine, Paris

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT00116454 - Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis | Biotech Hunter | Biotech Hunter